Hospital Alvaro Cunqueiro

Research siteFast reply

Spain Estrada Clara Campoamor No 341, 36312 Vigo, Spain

49 trials recruiting
HIV infection · Migraine · Non-small cell lung cancer
Adults and children

About Specializations

Hospital Alvaro Cunqueiro in Vigo, Spain specialises in clinical trials of conditions such as HIV infection, Migraine, Non-small cell lung cancer, Arteriosclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

At Hospital Alvaro Cunqueiro, investigators are evaluating whether early use of candesartan can prevent a meaningful decline in heart function for genetic carriers of dilated cardiomyopathy, aiming to preserve left ventricular performance before symptoms appear.

Early pharmacologic intervention in at‑risk patients
Monitoring left ventricular ejection fraction as a primary endpoint
Assessing ventricular remodeling through imaging biomarkers

The cardiology unit is conducting three trials with a team of 48 investigators, focusing on innovative prevention strategies for heart muscle disease.

Congenital, Hereditary, and Neonatal Diseases

The department is dedicated to studying hereditary forms of dilated cardiomyopathy, specifically targeting individuals who carry disease‑causing variants but have not yet manifested clinical signs, to evaluate the protective effect of early therapy.

Genetic screening and identification of at‑risk family members
Placebo‑controlled assessment of disease progression
Long‑term safety monitoring of ARB treatment in asymptomatic carriers

With 48 researchers involved, the site’s three clinical trials aim to translate genetic insights into preventive care for inherited heart conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Estrada Clara Campoamor No 34136312 VigoSpain

Open in maps ↗

Recruiting now: 49 trials
Conditions studied: 94

More sites in Vigo Spain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

120 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Spain

Participants:18–64 years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Recruiting

Investigational

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational

Spain

Participants:18–64 years
Sponsor:Zenas Biopharma (USA) LLC

Contact Research Centre

Primary progressive multiple sclerosis

Recruiting

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational

Spain

Participants:18–64 years
Sponsor:Zenas Biopharma (USA) LLC

Contact Research Centre

Small cell lung cancer+2

Recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:BioNTech SE

Contact Research Centre

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Zilebesiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Laroprovstat
Sponsor:AstraZeneca AB

Contact Research Centre

Squamous cell carcinoma of lung+6

Recruiting

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:BNT327
Sponsor:BioNTech SE

Contact Research Centre

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Recruiting

Registered drug

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Baxdrostat
Sponsor:AstraZeneca AB

Contact Research Centre

Partial seizures

Recruiting

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:BHV-7000
Sponsor:Biohaven Therapeutics Ltd.

Contact Research Centre

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo

Spain

Participants:65+ years · Healthy volunteers
Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
Sponsor:GlaxoSmithKline Biologicals

Contact Research Centre

Malignant peritoneal neoplasm+2

Recruiting

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Azenosertib
Sponsor:K-Group Beta Inc.

Contact Research Centre

HIV infection

Recruiting

Switching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study

Registered drugNo placebo

Switching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Abacavir
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites